drugset / Trial / NCT06603623
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Timeline
- Start
- 2024-10-10
- Primary completion
- 2025-03-24
- Completion
- 2025-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BHV-2100 | Unknown | 75 mg | — |
| Subject | BHV-2100 | Unknown | 150 mg | — |